Acurx Pharmaceuticals LLC (ACXP) - Total Assets
Based on the latest financial reports, Acurx Pharmaceuticals LLC (ACXP) holds total assets worth $9.54 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See how leveraged is Acurx Pharmaceuticals LLC's balance sheet to measure how much of total assets are equity-financed.
Acurx Pharmaceuticals LLC - Total Assets Trend (2019–2025)
This chart illustrates how Acurx Pharmaceuticals LLC's total assets have evolved over time, based on quarterly financial data. Check ACXP cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Acurx Pharmaceuticals LLC - Asset Composition Analysis
Current Asset Composition (December 2025)
Acurx Pharmaceuticals LLC's total assets of $9.54 Billion consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 98264.7% |
| Accounts Receivable | $48.42K | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Acurx Pharmaceuticals LLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ACXP market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Acurx Pharmaceuticals LLC's current assets represent 100.0% of total assets in 2025, unchanged from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 98264.7% of total assets in 2025, up from 98.1% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
Acurx Pharmaceuticals LLC Competitors by Total Assets
Key competitors of Acurx Pharmaceuticals LLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Acurx Pharmaceuticals LLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.66 | 1.93 | 9.09 |
| Quick Ratio | 3.66 | 1.93 | 9.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.73 Billion | $2.31 Million | $15.52 Million |
Acurx Pharmaceuticals LLC - Advanced Valuation Insights
This section examines the relationship between Acurx Pharmaceuticals LLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.13 |
| Latest Market Cap to Assets Ratio | 0.57 |
| Asset Growth Rate (YoY) | 99.3% |
| Total Assets | $7.69 Million |
| Market Capitalization | $4.40 Million USD |
Valuation Analysis
Below Book Valuation: The market values Acurx Pharmaceuticals LLC's assets below their book value (0.57x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Acurx Pharmaceuticals LLC's assets grew by 99.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Acurx Pharmaceuticals LLC (2019–2025)
The table below shows the annual total assets of Acurx Pharmaceuticals LLC from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $7.69 Million | +99.32% |
| 2024-12-31 | $3.86 Million | -49.96% |
| 2023-12-31 | $7.71 Million | -17.78% |
| 2022-12-31 | $9.38 Million | -29.25% |
| 2021-12-31 | $13.25 Million | +311.11% |
| 2020-12-31 | $3.22 Million | +27.36% |
| 2019-12-31 | $2.53 Million | -- |
About Acurx Pharmaceuticals LLC
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potenti… Read more